体外膜氧合期间血液灌流:纳入8,151例患者的更新系统评价与荟萃分析
主要终点全因死亡率无显著差异(OR 0.98, 95%CI 0.49-1.94, P=0.95, I2=76%)。但RCT亚组中ECMO+HP死亡率显著更高(OR 4.96, 95%CI 1.67-14.77, P=0.004)。按ECMO类型和病因亚组均未见生存获益。TSA提示证据不足以确认死亡率获益,多数研究存在中至重度偏倚风险。
要点
- 总体而言,ECMO+HP与单纯ECMO相比全因死亡率无显著差异(OR 0.98, 95%CI 0.49-1.94, P=0.95)。
- 在RCT中,ECMO+HP组的死亡率显著高于单纯ECMO组(OR 4.96, 95%CI 1.67-14.77, P=0.004)。
- VA-ECMO亚组(OR 0.80, 95%CI 0.41-1.58)和VV-ECMO亚组(OR 1.23, 95%CI 0.30-4.99)均未见生存获益。
- VA-ECMO患者中,心源性休克(OR 0.58, 95%CI 0.31-1.09)和心脏骤停(OR 2.42, 95%CI 0.71-8.25)亚组均无死亡率获益。
- TSA提示证据不足以确认死亡率获益,且多数研究存在中至重度偏倚风险。
适用人群与场景
- 接受体外膜氧合(ECMO)的成人患者,包括VA-ECMO和VV-ECMO。
- 纳入研究比较ECMO联合血液灌流(ECMO+HP)与单纯ECMO。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 主要终点全因死亡率:ECMO+HP vs 单纯ECMO无显著差异(OR 0.98, 95%CI 0.49-1.94; P=0.95; I2=76%)。
- RCT亚组中ECMO+HP死亡率显著更高(OR 4.96, 95%CI 1.67-14.77; P=0.004; I2=34%);非RCT亚组无显著差异(OR 0.58, 95%CI 0.25-1.33; P=0.20; I2=79%)。
- VA-ECMO亚组(OR 0.80, 95%CI 0.41-1.58; P=0.53; I2=47%)和VV-ECMO亚组(OR 1.23, 95%CI 0.30-4.99; P=0.77; I2=77%)均无生存获益。
- VA-ECMO患者中,心源性休克亚组(OR 0.58, 95%CI 0.31-1.09; P=0.09; I2=22%)和心脏骤停亚组(OR 2.42, 95%CI 0.71-8.25; P=0.16; I2=26%)均无死亡率获益。
- 其他临床结局或并发症无显著差异,TSA提示证据不足以确认死亡率获益。
- 多数研究存在中至重度偏倚风险。
证据类型、等级与局限
- 偏倚风险评估使用RoB 2.0和ROBINS-I,多数研究为中度至重度偏倚风险。
- 局限性:纳入研究以非RCT为主,异质性高(I2最高达79%),TSA提示证据不足。
对床旁实践的改变
- 当前证据不支持在ICU中常规对ECMO患者联合使用血液灌流。
- 在RCT中ECMO+HP可能增加死亡风险,临床决策时应谨慎。
- 适用人群为接受ECMO的成人患者,不适用于原文未提及的人群。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: This systematic review and meta-analysis evaluated the clinical efficacy and safety of hemoperfusion in adults receiving extracorporeal membrane oxygenation (ECMO).
METHODS: We systematically searched PubMed, Embase, the Cochrane Library, CNKI, and CBM for studies comparing ECMO plus hemoperfusion (ECMO + HP) with ECMO alone in adult patients. The primary outcome was all-cause mortality. Prespecified subgroup analyses were conducted according to study design (RCT vs non-RCT), ECMO type (VA vs VV), and etiology (cardiogenic shock vs cardiac arrest). Risk of bias was assessed using RoB 2.0 and ROBINS-I, and Trial Sequential Analysis (TSA) was performed. The systematic review was registered with PROSPERO (CRD42025643149) and conducted in accordance with PRISMA guidelines.
RESULTS: Thirteen studies involving 8,151 patients were included, comprising three RCTs and ten non-RCTs. Overall, ECMO + HP did not significantly reduce all-cause mortality compared with ECMO alone (OR 0.98, 95% CI 0.49-1.94; P = 0.95; I2 = 76%). However, mortality was higher with ECMO + HP in RCTs (OR 4.96, 95% CI 1.67-14.77; P = 0.004; I2 = 34%), whereas no significant difference was observed in non-RCTs (OR 0.58, 95% CI 0.25-1.33; P = 0.20; I2 = 79%). Subgroup analyses by ECMO type showed no survival benefit with either VA-ECMO (OR 0.80, 95% CI 0.41-1.58; P = 0.53; I2 = 47%) or VV-ECMO (OR 1.23, 95% CI 0.30-4.99; P = 0.77; I2 = 77%). Among VA-ECMO patients, etiology-based analyses showed no mortality benefit in cardiogenic shock (OR 0.58, 95% CI 0.31-1.09; P = 0.09; I2 = 22%) or cardiac arrest (OR 2.42, 95% CI 0.71-8.25; P = 0.16; I2 = 26%). No significant differences were identified in other clinical outcomes or complications, and TSA indicated that the evidence remains insufficient to confirm a mortality benefit. Most studies were at moderate to serious risk of bias.
CONCLUSION: In patients receiving extracorporeal membrane oxygenation, hemoperfusion did not reduce mortality and may be associated with increased mortality in randomized controlled trials. Current evidence does not support routine use of ECMO + HP in ICU condition.
参考来源
- Xie T, Yang C, Tao H, et al. Hemoperfusion during extracorporeal membrane oxygenation: an updated systematic review and meta-analysis of 8,151 patients. Crit Care. 2026. PMID: 42472846. doi:10.1186/s13054-026-06203-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。